Pfizer Inc, maker of COVID-19 vaccineThe company, with an equity value of $2.26 billion, will acquire all the shares it has not yet held in Trillium Therapeutics Inc., a maker of immune cancer drugs.
Pfizer Inc will buy Cambridge, Massachusetts-based Trillium for $18.50 a share, the two companies announced on Monday. This price represents a premium of 118% over its 60-day weighted average price.
Pfizer Inc invested 25 million US dollars in Trillium last September.